PMID- 27354481
OWN - NLM
STAT- MEDLINE
DCOM- 20170721
LR  - 20221207
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 34
IP  - 25
DP  - 2016 Sep 1
TI  - Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line 
      Treatment of Advanced Non-Small-Cell Lung Cancer.
PG  - 2969-79
LID - 10.1200/JCO.2016.66.9861 [doi]
AB  - PURPOSE: Nivolumab, a fully human immunoglobulin G4 programmed death-1 immune 
      checkpoint inhibitor antibody, has demonstrated improved survival in previously 
      treated patients with advanced non-small-cell lung cancer (NSCLC). CheckMate 012, 
      a phase I, multicohort study, was conducted to explore the safety and efficacy of 
      nivolumab as monotherapy or combined with current standard therapies in 
      first-line advanced NSCLC. Here, we report results for nivolumab plus 
      platinum-based doublet chemotherapy (PT-DC). PATIENTS AND METHODS: Patients (N = 
      56) received nivolumab (intravenously) plus PT-DC concurrently every 3 weeks for 
      four cycles followed by nivolumab alone until progression or unacceptable 
      toxicity. Regimens were nivolumab 10 mg/kg plus gemcitabine-cisplatin (squamous) 
      or pemetrexed-cisplatin (nonsquamous) or nivolumab 5 or 10 mg/kg plus 
      paclitaxel-carboplatin (all histologies). The primary objective was to assess 
      safety and tolerability. Secondary objectives included objective response rate 
      and 24-week progression-free survival rate (per Response Evaluation Criteria in 
      Solid Tumors version 1.1); exploratory objectives included overall survival (OS) 
      and response by tumor programmed death ligand-1 expression. RESULTS: No 
      dose-limiting toxicities occurred during the first 6 weeks of treatment. 
      Forty-five percent of patients (25 of 56 patients) reported grade 3 or 4 
      treatment-related adverse events (AEs); 7% of patients (n = 4) had pneumonitis. 
      Twenty-one percent of patients (n = 12) discontinued all study therapy as a 
      result of treatment-related AEs. Objective response rates for nivolumab 10 mg/kg 
      plus gemcitabine-cisplatin, nivolumab 10 mg/kg plus pemetrexed-cisplatin, 
      nivolumab 10 mg/kg plus paclitaxel-carboplatin, and nivolumab 5 mg/kg plus 
      paclitaxel-carboplatin were 33%, 47%, 47%, and 43%, respectively; 24-week 
      progression-free survival rates were 51%, 71%, 38%, and 51%, respectively; 2-year 
      OS rates were 25%, 33%, 27%, and 62%, respectively. Responses were achieved 
      regardless of tumor programmed death ligand-1 expression. CONCLUSION: The safety 
      profile of nivolumab plus PT-DC was consistent with that expected for individual 
      agents; however, treatment discontinuation related to AEs was greater with the 
      combination. Encouraging activity was observed, especially for the nivolumab 5 
      mg/kg plus paclitaxel-carboplatin group, with a 2-year OS rate of 62%.
CI  - (c) 2016 by American Society of Clinical Oncology.
FAU - Rizvi, Naiyer A
AU  - Rizvi NA
AD  - Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, 
      New York, NY; Julie R. Brahmer, The Sidney Kimmel Comprehensive Cancer Center at 
      Johns Hopkins, Baltimore, MD; Rosalyn A. Juergens, Juravinski Cancer Centre at 
      McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, 
      Ottawa; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto, Ontario, 
      Canada; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Scott 
      Gettinger, Yale Cancer Center, New Haven, CT; Laura Q. Chow, University of 
      Washington, Seattle, WA; David E. Gerber, University of Texas Southwestern 
      Medical Center, Dallas, TX; Jonathan W. Goldman, University of California, Los 
      Angeles, Los Angeles, CA; Allen C. Chen, Yun Shen, Faith E. Nathan, and 
      Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ; and Scott Antonia, 
      H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. 
      nar2144@cumc.columbia.edu.
FAU - Hellmann, Matthew D
AU  - Hellmann MD
AD  - Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, 
      New York, NY; Julie R. Brahmer, The Sidney Kimmel Comprehensive Cancer Center at 
      Johns Hopkins, Baltimore, MD; Rosalyn A. Juergens, Juravinski Cancer Centre at 
      McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, 
      Ottawa; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto, Ontario, 
      Canada; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Scott 
      Gettinger, Yale Cancer Center, New Haven, CT; Laura Q. Chow, University of 
      Washington, Seattle, WA; David E. Gerber, University of Texas Southwestern 
      Medical Center, Dallas, TX; Jonathan W. Goldman, University of California, Los 
      Angeles, Los Angeles, CA; Allen C. Chen, Yun Shen, Faith E. Nathan, and 
      Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ; and Scott Antonia, 
      H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
FAU - Brahmer, Julie R
AU  - Brahmer JR
AD  - Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, 
      New York, NY; Julie R. Brahmer, The Sidney Kimmel Comprehensive Cancer Center at 
      Johns Hopkins, Baltimore, MD; Rosalyn A. Juergens, Juravinski Cancer Centre at 
      McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, 
      Ottawa; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto, Ontario, 
      Canada; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Scott 
      Gettinger, Yale Cancer Center, New Haven, CT; Laura Q. Chow, University of 
      Washington, Seattle, WA; David E. Gerber, University of Texas Southwestern 
      Medical Center, Dallas, TX; Jonathan W. Goldman, University of California, Los 
      Angeles, Los Angeles, CA; Allen C. Chen, Yun Shen, Faith E. Nathan, and 
      Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ; and Scott Antonia, 
      H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
FAU - Juergens, Rosalyn A
AU  - Juergens RA
AD  - Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, 
      New York, NY; Julie R. Brahmer, The Sidney Kimmel Comprehensive Cancer Center at 
      Johns Hopkins, Baltimore, MD; Rosalyn A. Juergens, Juravinski Cancer Centre at 
      McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, 
      Ottawa; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto, Ontario, 
      Canada; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Scott 
      Gettinger, Yale Cancer Center, New Haven, CT; Laura Q. Chow, University of 
      Washington, Seattle, WA; David E. Gerber, University of Texas Southwestern 
      Medical Center, Dallas, TX; Jonathan W. Goldman, University of California, Los 
      Angeles, Los Angeles, CA; Allen C. Chen, Yun Shen, Faith E. Nathan, and 
      Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ; and Scott Antonia, 
      H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
FAU - Borghaei, Hossein
AU  - Borghaei H
AD  - Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, 
      New York, NY; Julie R. Brahmer, The Sidney Kimmel Comprehensive Cancer Center at 
      Johns Hopkins, Baltimore, MD; Rosalyn A. Juergens, Juravinski Cancer Centre at 
      McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, 
      Ottawa; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto, Ontario, 
      Canada; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Scott 
      Gettinger, Yale Cancer Center, New Haven, CT; Laura Q. Chow, University of 
      Washington, Seattle, WA; David E. Gerber, University of Texas Southwestern 
      Medical Center, Dallas, TX; Jonathan W. Goldman, University of California, Los 
      Angeles, Los Angeles, CA; Allen C. Chen, Yun Shen, Faith E. Nathan, and 
      Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ; and Scott Antonia, 
      H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
FAU - Gettinger, Scott
AU  - Gettinger S
AD  - Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, 
      New York, NY; Julie R. Brahmer, The Sidney Kimmel Comprehensive Cancer Center at 
      Johns Hopkins, Baltimore, MD; Rosalyn A. Juergens, Juravinski Cancer Centre at 
      McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, 
      Ottawa; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto, Ontario, 
      Canada; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Scott 
      Gettinger, Yale Cancer Center, New Haven, CT; Laura Q. Chow, University of 
      Washington, Seattle, WA; David E. Gerber, University of Texas Southwestern 
      Medical Center, Dallas, TX; Jonathan W. Goldman, University of California, Los 
      Angeles, Los Angeles, CA; Allen C. Chen, Yun Shen, Faith E. Nathan, and 
      Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ; and Scott Antonia, 
      H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
FAU - Chow, Laura Q
AU  - Chow LQ
AD  - Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, 
      New York, NY; Julie R. Brahmer, The Sidney Kimmel Comprehensive Cancer Center at 
      Johns Hopkins, Baltimore, MD; Rosalyn A. Juergens, Juravinski Cancer Centre at 
      McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, 
      Ottawa; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto, Ontario, 
      Canada; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Scott 
      Gettinger, Yale Cancer Center, New Haven, CT; Laura Q. Chow, University of 
      Washington, Seattle, WA; David E. Gerber, University of Texas Southwestern 
      Medical Center, Dallas, TX; Jonathan W. Goldman, University of California, Los 
      Angeles, Los Angeles, CA; Allen C. Chen, Yun Shen, Faith E. Nathan, and 
      Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ; and Scott Antonia, 
      H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
FAU - Gerber, David E
AU  - Gerber DE
AD  - Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, 
      New York, NY; Julie R. Brahmer, The Sidney Kimmel Comprehensive Cancer Center at 
      Johns Hopkins, Baltimore, MD; Rosalyn A. Juergens, Juravinski Cancer Centre at 
      McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, 
      Ottawa; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto, Ontario, 
      Canada; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Scott 
      Gettinger, Yale Cancer Center, New Haven, CT; Laura Q. Chow, University of 
      Washington, Seattle, WA; David E. Gerber, University of Texas Southwestern 
      Medical Center, Dallas, TX; Jonathan W. Goldman, University of California, Los 
      Angeles, Los Angeles, CA; Allen C. Chen, Yun Shen, Faith E. Nathan, and 
      Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ; and Scott Antonia, 
      H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
FAU - Laurie, Scott A
AU  - Laurie SA
AD  - Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, 
      New York, NY; Julie R. Brahmer, The Sidney Kimmel Comprehensive Cancer Center at 
      Johns Hopkins, Baltimore, MD; Rosalyn A. Juergens, Juravinski Cancer Centre at 
      McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, 
      Ottawa; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto, Ontario, 
      Canada; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Scott 
      Gettinger, Yale Cancer Center, New Haven, CT; Laura Q. Chow, University of 
      Washington, Seattle, WA; David E. Gerber, University of Texas Southwestern 
      Medical Center, Dallas, TX; Jonathan W. Goldman, University of California, Los 
      Angeles, Los Angeles, CA; Allen C. Chen, Yun Shen, Faith E. Nathan, and 
      Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ; and Scott Antonia, 
      H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
FAU - Goldman, Jonathan W
AU  - Goldman JW
AD  - Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, 
      New York, NY; Julie R. Brahmer, The Sidney Kimmel Comprehensive Cancer Center at 
      Johns Hopkins, Baltimore, MD; Rosalyn A. Juergens, Juravinski Cancer Centre at 
      McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, 
      Ottawa; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto, Ontario, 
      Canada; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Scott 
      Gettinger, Yale Cancer Center, New Haven, CT; Laura Q. Chow, University of 
      Washington, Seattle, WA; David E. Gerber, University of Texas Southwestern 
      Medical Center, Dallas, TX; Jonathan W. Goldman, University of California, Los 
      Angeles, Los Angeles, CA; Allen C. Chen, Yun Shen, Faith E. Nathan, and 
      Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ; and Scott Antonia, 
      H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
FAU - Shepherd, Frances A
AU  - Shepherd FA
AD  - Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, 
      New York, NY; Julie R. Brahmer, The Sidney Kimmel Comprehensive Cancer Center at 
      Johns Hopkins, Baltimore, MD; Rosalyn A. Juergens, Juravinski Cancer Centre at 
      McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, 
      Ottawa; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto, Ontario, 
      Canada; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Scott 
      Gettinger, Yale Cancer Center, New Haven, CT; Laura Q. Chow, University of 
      Washington, Seattle, WA; David E. Gerber, University of Texas Southwestern 
      Medical Center, Dallas, TX; Jonathan W. Goldman, University of California, Los 
      Angeles, Los Angeles, CA; Allen C. Chen, Yun Shen, Faith E. Nathan, and 
      Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ; and Scott Antonia, 
      H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
FAU - Chen, Allen C
AU  - Chen AC
AD  - Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, 
      New York, NY; Julie R. Brahmer, The Sidney Kimmel Comprehensive Cancer Center at 
      Johns Hopkins, Baltimore, MD; Rosalyn A. Juergens, Juravinski Cancer Centre at 
      McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, 
      Ottawa; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto, Ontario, 
      Canada; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Scott 
      Gettinger, Yale Cancer Center, New Haven, CT; Laura Q. Chow, University of 
      Washington, Seattle, WA; David E. Gerber, University of Texas Southwestern 
      Medical Center, Dallas, TX; Jonathan W. Goldman, University of California, Los 
      Angeles, Los Angeles, CA; Allen C. Chen, Yun Shen, Faith E. Nathan, and 
      Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ; and Scott Antonia, 
      H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
FAU - Shen, Yun
AU  - Shen Y
AD  - Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, 
      New York, NY; Julie R. Brahmer, The Sidney Kimmel Comprehensive Cancer Center at 
      Johns Hopkins, Baltimore, MD; Rosalyn A. Juergens, Juravinski Cancer Centre at 
      McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, 
      Ottawa; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto, Ontario, 
      Canada; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Scott 
      Gettinger, Yale Cancer Center, New Haven, CT; Laura Q. Chow, University of 
      Washington, Seattle, WA; David E. Gerber, University of Texas Southwestern 
      Medical Center, Dallas, TX; Jonathan W. Goldman, University of California, Los 
      Angeles, Los Angeles, CA; Allen C. Chen, Yun Shen, Faith E. Nathan, and 
      Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ; and Scott Antonia, 
      H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
FAU - Nathan, Faith E
AU  - Nathan FE
AD  - Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, 
      New York, NY; Julie R. Brahmer, The Sidney Kimmel Comprehensive Cancer Center at 
      Johns Hopkins, Baltimore, MD; Rosalyn A. Juergens, Juravinski Cancer Centre at 
      McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, 
      Ottawa; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto, Ontario, 
      Canada; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Scott 
      Gettinger, Yale Cancer Center, New Haven, CT; Laura Q. Chow, University of 
      Washington, Seattle, WA; David E. Gerber, University of Texas Southwestern 
      Medical Center, Dallas, TX; Jonathan W. Goldman, University of California, Los 
      Angeles, Los Angeles, CA; Allen C. Chen, Yun Shen, Faith E. Nathan, and 
      Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ; and Scott Antonia, 
      H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
FAU - Harbison, Christopher T
AU  - Harbison CT
AD  - Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, 
      New York, NY; Julie R. Brahmer, The Sidney Kimmel Comprehensive Cancer Center at 
      Johns Hopkins, Baltimore, MD; Rosalyn A. Juergens, Juravinski Cancer Centre at 
      McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, 
      Ottawa; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto, Ontario, 
      Canada; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Scott 
      Gettinger, Yale Cancer Center, New Haven, CT; Laura Q. Chow, University of 
      Washington, Seattle, WA; David E. Gerber, University of Texas Southwestern 
      Medical Center, Dallas, TX; Jonathan W. Goldman, University of California, Los 
      Angeles, Los Angeles, CA; Allen C. Chen, Yun Shen, Faith E. Nathan, and 
      Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ; and Scott Antonia, 
      H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
FAU - Antonia, Scott
AU  - Antonia S
AD  - Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, 
      New York, NY; Julie R. Brahmer, The Sidney Kimmel Comprehensive Cancer Center at 
      Johns Hopkins, Baltimore, MD; Rosalyn A. Juergens, Juravinski Cancer Centre at 
      McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, 
      Ottawa; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto, Ontario, 
      Canada; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Scott 
      Gettinger, Yale Cancer Center, New Haven, CT; Laura Q. Chow, University of 
      Washington, Seattle, WA; David E. Gerber, University of Texas Southwestern 
      Medical Center, Dallas, TX; Jonathan W. Goldman, University of California, Los 
      Angeles, Los Angeles, CA; Allen C. Chen, Yun Shen, Faith E. Nathan, and 
      Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ; and Scott Antonia, 
      H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
LA  - eng
SI  - ClinicalTrials.gov/NCT01454102
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Clinical Trial, Phase I
PT  - Journal Article
DEP - 20160627
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (B7-H1 Antigen)
RN  - 0 (CD274 protein, human)
RN  - 0 (KRAS protein, human)
RN  - 04Q9AIZ7NO (Pemetrexed)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 31YO63LBSN (Nivolumab)
RN  - BG3F62OND5 (Carboplatin)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
RN  - Q20Q21Q62J (Cisplatin)
RN  - 0 (Gemcitabine)
SB  - IM
CIN - J Clin Oncol. 2016 Sep 1;34(25):2953-5. PMID: 27382094
CIN - Nat Rev Clin Oncol. 2016 Oct;13(10 ):595-6. PMID: 27620712
CIN - J Thorac Dis. 2016 Oct;8(10 ):E1254-E1256. PMID: 27867601
MH  - Aged
MH  - Antibodies, Monoclonal/*administration & dosage/*adverse effects
MH  - Antineoplastic Combined Chemotherapy Protocols/*adverse effects/*therapeutic use
MH  - B7-H1 Antigen/biosynthesis
MH  - Carboplatin/administration & dosage/adverse effects
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics/metabolism
MH  - Cisplatin/administration & dosage/adverse effects
MH  - Cohort Studies
MH  - Deoxycytidine/administration & dosage/adverse effects/analogs & derivatives
MH  - Disease-Free Survival
MH  - Dose-Response Relationship, Drug
MH  - ErbB Receptors/genetics
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/genetics/metabolism
MH  - Male
MH  - Middle Aged
MH  - Nivolumab
MH  - Pemetrexed/administration & dosage/adverse effects
MH  - Proto-Oncogene Proteins p21(ras)/genetics
MH  - Survival Rate
MH  - Gemcitabine
PMC - PMC5569693
COIS- Authors' disclosures of potential conflicts of interest are found in the article 
      online at www.jco.org. Author contributions are found at the end of this article.
EDAT- 2016/06/30 06:00
MHDA- 2017/07/22 06:00
PMCR- 2016/10/01
CRDT- 2016/06/30 06:00
PHST- 2016/06/30 06:00 [entrez]
PHST- 2016/06/30 06:00 [pubmed]
PHST- 2017/07/22 06:00 [medline]
PHST- 2016/10/01 00:00 [pmc-release]
AID - JCO.2016.66.9861 [pii]
AID - 669861 [pii]
AID - 10.1200/JCO.2016.66.9861 [doi]
PST - ppublish
SO  - J Clin Oncol. 2016 Sep 1;34(25):2969-79. doi: 10.1200/JCO.2016.66.9861. Epub 2016 
      Jun 27.